FBXO4 and non-small cell lung carcinoma: Particularly, overexpression of Fbxo4 effectively enhances the sensitivity of NSCLC cells to chemotherapeutic compounds, including cisplatin or paclitaxel, highlighting the therapeutic potential by targeting Fbxo4-Mcl-1 signaling for treating NSCLC.